Janus Henderson Group PLC increased its stake in Eli Lilly and Company (NYSE:LLY) by 7,093.5% during the second quarter, according to its most recent filing with the SEC. The fund owned 9,353,275 shares of the company’s stock after buying an additional 9,223,251 shares during the quarter. Eli Lilly and accounts for approximately 0.5% of Janus Henderson Group PLC’s portfolio, making the stock its 28th largest holding. Janus Henderson Group PLC owned 0.89% of Eli Lilly and worth $769,774,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of LLY. Bank of The Ozarks boosted its holdings in shares of Eli Lilly and by 24.9% in the 1st quarter. Bank of The Ozarks now owns 8,723 shares of the company’s stock worth $734,000 after buying an additional 1,740 shares during the last quarter. Stifel Financial Corp boosted its holdings in shares of Eli Lilly and by 2.6% in the 1st quarter. Stifel Financial Corp now owns 709,703 shares of the company’s stock worth $59,657,000 after buying an additional 17,892 shares during the last quarter. ARS Investment Partners LLC boosted its holdings in shares of Eli Lilly and by 7.3% in the 1st quarter. ARS Investment Partners LLC now owns 2,950 shares of the company’s stock worth $248,000 after buying an additional 200 shares during the last quarter. Wayne Hummer Investments L.L.C. boosted its holdings in shares of Eli Lilly and by 105.4% in the 1st quarter. Wayne Hummer Investments L.L.C. now owns 6,775 shares of the company’s stock worth $570,000 after buying an additional 3,477 shares during the last quarter. Finally, Spinnaker Trust purchased a new position in shares of Eli Lilly and in the 1st quarter worth about $226,000. 76.61% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This article was posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://www.watchlistnews.com/eli-lilly-and-company-lly-shares-bought-by-janus-henderson-group-plc/1721133.html.

Eli Lilly and Company (NYSE:LLY) opened at $83.68 on Thursday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03. The firm has a market cap of $91,919.42, a P/E ratio of 20.41, a P/E/G ratio of 1.84 and a beta of 0.34. Eli Lilly and Company has a 52-week low of $64.18 and a 52-week high of $89.09.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.03 by $0.02. The company had revenue of $5.66 billion for the quarter, compared to analysts’ expectations of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. Eli Lilly and’s revenue for the quarter was up 9.0% compared to the same quarter last year. During the same period in the prior year, the business earned $0.88 earnings per share. analysts anticipate that Eli Lilly and Company will post 4.21 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Wednesday, November 15th will be given a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.49%. The ex-dividend date is Tuesday, November 14th. Eli Lilly and’s dividend payout ratio (DPR) is 98.58%.

In related news, SVP Alfonso G. Zulueta sold 2,003 shares of the company’s stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $83.67, for a total value of $167,591.01. Following the transaction, the senior vice president now directly owns 43,580 shares in the company, valued at $3,646,338.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Lilly Endowment Inc sold 180,000 shares of the company’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $81.06, for a total transaction of $14,590,800.00. Following the completion of the transaction, the insider now owns 123,865,804 shares in the company, valued at $10,040,562,072.24. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 772,003 shares of company stock worth $64,837,441. 0.20% of the stock is owned by company insiders.

A number of equities analysts recently weighed in on the stock. Morgan Stanley boosted their price target on shares of Eli Lilly and from $86.00 to $90.00 and gave the stock an “equal weight” rating in a report on Tuesday. BMO Capital Markets set a $73.00 price objective on shares of Eli Lilly and and gave the company a “sell” rating in a report on Wednesday, November 1st. Zacks Investment Research downgraded shares of Eli Lilly and from a “buy” rating to a “hold” rating in a report on Monday, October 30th. Berenberg Bank reaffirmed a “buy” rating and set a $98.00 price objective on shares of Eli Lilly and in a report on Thursday, October 26th. Finally, Leerink Swann upped their price objective on shares of Eli Lilly and from $92.00 to $93.00 and gave the company a “market perform” rating in a report on Monday, October 23rd. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $89.97.

Eli Lilly and Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.